Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: A review

Vaccine

Volumn 24, Issue 13, 2006, Pages 2440-2448

  Jacquet, J M ^a   Begue P ^b   Grimprel, E ^b   Reinert, P ^c   Sandbu, S ^d   Silfverdal, S A ^e   Faldella, G ^f   Nolan, T ^g   Lambert, S ^g   Richmond, P ^h   Marshall, H ⁱ   Roberton, D ⁱ   Schuerman, L ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c Hôpital Intercommunal De Créteil   (France)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Acellular pertussis vaccine; Booster vaccination; Immunogenicity; Vaccine associated adverse events

Indexed keywords

ACELLULAR VACCINE; ANTIBODY; BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DIPHTHERIA; DRUG FEVER; DRUG SAFETY; EDEMA; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RECTUM TEMPERATURE; SKIN INDURATION; TETANUS; VACCINATION REACTION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED;

EID: 33344464742     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.12.009     Document Type: Article

References (47)

1. K.M. Edwards, M. Decker, and E.A. Mortimer Pertussis vaccine S.A. Plotkin WA. Orenstein Vaccines 3rd ed. 1999 WB Saunders Philadelphia 293 344
2. Center for Disease Control and Prevention. Pertussis, United States, 1997-2000. MMWR Morbid Mortal Wkly Rep 2002;51:73-6.
3. H. Therre, and S. Baron Pertussis immunisation in Europe - the situation in late 1999 Eur Surveill 5 1 2000 6 10
4. D. Guris, P.M. Strebel, and B. Bardenheier Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996 Clin Infect Dis 28 6 1999 1230 1237
5. J.K. van Wijngaarden, J. Huisman, J.W. van der Meer, and H.K. Visser Pertussis: current epidemiology and recommendations of the Health Council with regard to vaccination policy Ned Tijdschr Geneeskd 144 48 2000 2297 2301
6. W. von König, S. Halperin, N. Riffelman, and N. Guiso Pertussis of adults and infants Lancet Infectious Diseases 2 2002 744 750
7. A. Grimprel, S. Baron, and Lévy-Bruhl Influence of vaccination coverage on pertussis transmission in France Lancet 354 1999 1699 1700
8. N.S. Crowcroft, R. Booy, T. Harrison, J. Spicer, J. Britto, and Q. Mok Severe and unrecognised: pertussis in UK infants Arch Dis Child 88 2003 802 806
9. D. Floret Les décès par infection bactérienne communautaire. Enquête dans les services de réanimation pédiatrique français Arch Pédiatr 8 Suppl 4 2001 705 711
10. S. Cordova, M. Gilles, and M. Beers The outbreak that had to happen: Bordetella pertussis in north-west Western Australia in 1999 Commun Dis Intell 24 2000 375 379
11. I. Bonmarin, E. Laurent, N. Guiso, D. Levy-Bruhl les participants Renacoq Renacoq: surveillance de la coqueluche à l'hôpital en 2001 BEH 4 2003 213 214
12. C. Belloni, A. De Silvestri, C. Tinelli, M.A. Avanzini, M. Marconi, and F. Strano Immunogenicity of a three-component acellular pertussis vaccine administered at birth Pediatrics 111 5 2003 1042 1045
13. K. Forsyth, M. Campins-Marti, and J. Caro New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative Clin Infect Dis 39 2004 1802 1809
14. Calendrier Vaccinal 2004. Avis du Conseil supérieur d'hygiène publique de France, BEH 2004;28-29:2121-26.
15. H.-J. Schmitt, K. Beutel, A. Schuind, M. Knuf, S. Wagner, and S. Müschenborn Reactogenicity and immunogenicity of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age J Pediatr 130 1997 616 623
16. M.E. Pichichero, K.M. Edwards, E.L. Anderson, M.B. Rennels, J.A. Englund, and D.E. Yerg Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year old children Pediatrics 105 1 2000 e11 http://www.pediatrics.org/cgi/content/full/ 105/1/e11
17. M.B. Rennels, M.A. Deloria, M.E. Pichichero, G.A. Losonsky, J.A. Englund, and B.D. Meade Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines Pediatrics 105 1 2000 e12 http://www.pediatrics.org/cgi/content/full/105/1/e12
18. A.E. Tozzi, A. Anemona, P. Stefanelli, S. Salmaso, M.L. Atti, and P. Mastrantonio Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines Pediatrics 107 2 2001 E25 http://www.pediatrics.org/cgi/content/full/107/2/e25
19. P.W. Annunziato, E.P. Rothstein, H.H. Bernstein, M.M. Blatter, K.S. Reisinger, and M.E. Pichichero comparison of a three-component acellular pertussis vaccine with a whole cell pertussis vaccine in 4- through 6-year old children Arch Ped Adolesc Med 148 5 1994 503 507
20. M.E. Melville-Smith, V.A. Seagroatt, and J.T. Watkins A comparison of enzyme linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera J Biol Stand 11 1983 137 144
21. M. Melville-Smith, and A. Balfour Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralization test J Med Microbiol 25 1988 279 283
22. K. Miyamura, S. Nisho, A. Ito, R. Murato, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration J Biol Stand 2 1974 189 201
23. K. Miyamura, S. Nisho, A. Ito, R. Murata, and R. Kono Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with rabbit skin method and practical application for sero epidemiological studies J Biol Stand 2 1974 203 209
24. Standard procedure for determining immunity to poliovirus using single microneutralisation test. WHO/EPI/Gen. 93.3.
25. L. Nilsson, G. Faldella, J.M. Jacquet, J. Storsaeter, S.A. Silfverdal, and L. Ekholm A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age Scand J Infect Dis 37 2005 221 229
26. P.C. Begue, E.M. Grimprel, M.D. Giovannangeli, and V.I. Abitbol Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents Pediatr Infect Dis 17 1998 804 809
27. Marshall H, Nolan T, Roberton D, Richmond P, Lambert S, Jacquet J-M, et al. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years. Vaccine; in press.
28. E. Grimprel, P. Bégué, I. Anjak, E. Njampeko, P. François, and N. Guiso Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France Clin Diagn Lab Immunol 3 1996 93 97
29. C.M. Ausiello, R. Lande, F. Urbani, B. Di Carlo, P. Stefanelli, and S. Salmaso Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine J Infect Dis 181 6 2000 1989 1995
30. T.M. Chapman, and K.L. Goa Reduced-antigen combined diphtheria-tetanus- acellular pertussis vaccine (Boostrix™) Drugs 63 13 2003 1407 1413
31. F. Zepp, B. Cheuvart, and J. Wolter Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (dTpa) in pre-school-aged children Presented at the 21st Annual Meeting of the European Society of Pediatric Infectious Diseases (ESPID) Taormina, Italy, April 2003 (Abstract 281)
32. B. Cheuvart, M. Burgess, F. Zepp, J. Mertsola, J. Wolter, and L. Schuerman Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model Vaccine 23 2004 336 342
33. S.A. Halperin, D. Scheifele, L. Barreto, C. Pim, R. Guasparini, and L. Medd Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age Pediatric Infect Dis J 18 1999 772 779
34. S.A. Halperin, D. Scheifele, E. Mills, R. Guasparini, G. Humphreys, and L. Barreto Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine Vaccine 21 2003 2298 2306
35. D.W. Scheifele, S.A. Halperin, and A.C. Ferguson Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens Vaccine 19 2001 4720 4726
36. D.M. Skowronski, V.P. Remple, J. Macnabb, K. Pielak, D.M. Patrick, and S.A. Halperin Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact Pediatrics 112 6 2003 e453 http://www.pediatrics.org/cgi/content/full/112/6/e453
37. C. Pim, and J. Farley Local reactions to kindergarten DPT boosters - Cranbrook Dis Surveill 9 1988 230 239
38. M. Blennow, and M. Granström Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants Pediatrics 84 1 1989 62 67
39. E.J. Woo, D.R. Burwen, S.N.M. Gatumu, R. Ball The Vaccine Adverse Event Reporting System (VAERS) Working Group Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System Clin Infect Dis 37 2003 351 358
40. M. Rennels Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines Semin Pediatr Infect Dis 14 2003 196 198
41. E. Ryan, L. Nilsson, N.I. Kjellman, L. Gotherfors, and K. Mills Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens Clin Exp Immunol 121 2000 193 200
42. ®) for fifth consecutive DTaP vaccine dose. Morb Mortal Wkly Rep 2003;52(38):921.
43. J. Joensuu, M. Lahdenkari, and S. Rapola Safety of four acellular pertussis combination vaccines given as a booster dose to six-year-old Presented at the 20th Annual Meeting of the European Society of Pediatric Infectious Diseases (ESPID) Vilnius 2002
44. ACIP. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccines as a five-dose series. MMWR Recomm Rep 2000;49(RR13):1-8.
45. S.A. Halperin, B.J. Eastwood, L. Barreto, B. Friesen, L. Medd, and W. Meekison Adverse reactions and antibody response to four doses of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life Vaccine 14 1996 767 772
46. R. Vergara, M. Tregnaghi, J. Ussher, S. Navarro, R. Rüttiman, and M. Potin Reduced-antigen DTPa-IPV vaccine as a booster for adolescents 10 to 14 years of age Eur J Pediatr 164 2005 377 382
47. C.L. Collins, P. Salt, N. McCarthy, T. Chantler, L. Lane, and F. Hemme Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children Vaccine 22 2004 4262 4269